United States

Profile: NxStage Medical Inc (NXTM.O)

NXTM.O on Nasdaq

2:58pm EST
Change (% chg)

$0.24 (+0.86%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

NxStage Medical, Inc., incorporated on October 20, 1998, is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. The Company offers its products and services to various markets, such as home, critical care and in-center. The Company's primary product, the System One, delivers the therapeutic flexibility and clinical benefits associated with dialysis machines that can be used by healthcare professionals and trained lay users alike in various settings, including patient homes, as well as traditional care settings, such as hospitals and dialysis centers. The Company operates NxStage Kidney Care dialysis centers that treat end-stage renal disease patients directly.

The NxStage System One is a hemodialysis system that is used to perform treatments during the day or at night, while sleeping. The Company also provides patients with the consumables and services, which are used for the treatment with the System One. These include The NxStage Cartridge, PureFlow SL and Premixed Dialysate, and Nx2me Connected Health. The NxStage Cartridge, which is a disposable, is an integrated treatment cartridge that loads into the System One. The cartridge incorporates a volumetric fluid management system and includes a pre-attached dialyzer. The PureFlow SL accessory prepares premixed dialysate fluid in batches before treatment in the patient's home using ordinary tap water and dialysate concentrate. The volume of fluids used varies with treatment options, prescription and setting. To accommodate patient travel with the System One or in other circumstances, in which the PureFlow SL is not available, the Company also supplies premixed dialysate in sterile five liter bags. The Nx2me Connected Health platform leverages cloud-based computing and wireless communications by using an application the Company has developed for the iPad. The Nx2me Connected Health application collects important System One cycler data, as well as patient information, such as blood pressure and weight.

The Company sells extracorporeal disposable products under its Medisystems brand that are primarily used for in-center hemodialysis treatments for end-stage renal disease (ESRD) patients. These products include hemodialysis blood tubing sets, arteriovenous (AV) fistula needles, apheresis needles, safety accessories and access management disposables. The Company's Streamline blood tubing sets enables providers to optimize dose delivery, and includes its LockSite needleless access sites, eliminating the need for sharp needles or guarded needles to be used with the tubing set in connection with dialysis therapy. In addition, its Streamline Express dialyzer features a pre-attached blood tubing set, which is designed to reduce the number of touch point contamination sites. AV fistula and apheresis needles have been designed to achieve a smooth blood flow throughout the treatment, intended to result in less clotting, lower pressure drops and less stress on the patient's blood. The Company also offers ButtonHole needles for hemodialysis therapies, which are used by patients that employ the constant-site technique, whereby a fistula needle is inserted in the same place each treatment. The Company also offers OneSite dual lumen needle.

System One

The System One segment is engaged in the sale and rental of the System One and PureFlow SL dialysate preparation equipment, and the sale of disposable products in the home and critical care markets. The Company markets and sells the System One to dialysis clinics in the United States and other markets, which in turn provide the System One to their ESRD patients for chronic home hemodialysis treatment. The Company offers a bio-medical training program, whereby it train bio-medical engineers on how to service and repair certain aspects of the System One in the critical care settings. The Company also supplies hospitals using the System One with related disposable cartridges and treatment fluids necessary to perform treatment.


The In-Center segment is engaged in the sale of blood tubing sets and needles for hemodialysis, primarily for the treatment of ESRD patients at dialysis clinics and needles for apheresis. The Company offers its products to independent dialysis clinics, as well as dialysis clinics that are part of national or regional chains. The In-Center segment markets its extracorporeal disposable products under the Medisystems brand.


The Services segment offers dialysis services provided to patients at its NxStage Kidney Care dialysis centers. The Company has approximately 20 centers open in over 20 states, of which approximately 10 has received Medicare certification. At the NxStage Kidney Care dialysis centers, the Company provides patients with a range of therapy options for both their clinical and lifestyle needs. For appropriate patients, such therapies may include home hemodialysis or more flexible in-center hemodialysis with the System One, and peritoneal dialysis.

The Company competes with Gambro, Fresenius, Nikkiso Co. Ltd., B. Braun Medical, Inc., Fresenius, Nipro Medical Corporation, JMS Co. Ltd. and DaVita.

Company Address

NxStage Medical Inc

350 Merrimack St
LAWRENCE   MA   01843-1748
P: +1978.6874700
F: +1302.6555049

Company Web Links